Full Industry-Pushing Agenda

The virtual event platform is now live!

Log in now

Following the Swapcard Login Instructions here or by viewing this video, to update your profile, review the upcoming agenda, check out our exhibitors, and start those all important conversations!

Not registered? Click here to register for the event

Day 1 – September 14: Keynotes & Commercial Excellence

9:00am - Opening C-Suite Interviews

Reuters Editorial 1-on-1 interview with Christophe, CEO, Takeda

  • Pioneer mobilization of global leaders to shape the principles, policies and partnerships needed in this challenging new context

More information will be revealed soon.

Christophe Weber President, Chief Executive Officer (CEO) and Representative Director Takeda Pharmaceutical Co., Ltd.

9:30 - Cement new diverse and collaborative business standards

Hello, Healthy World

  • When I worked as a physician, I encountered a fundamental question: "Why do people lose their lives because they cannot meet the proper treatment or drug?"
  • AI "Monshin"(interview), the "gateway to medical care," rapidly penetrates the medical institutions and patients.
  • Ubie empowers doctors and guides people to the right medical care. And we are ready to deliver the medicine to every patient who needs them.
  • How do pharmaceutical companies and Ubie collaborate to guide people to the right care and medicine? I will tell the story based on the actual case studies.

Yoshinori Abe MD, Co-Founder & CEO Ubie, Inc.

9:30 - Cement new diverse and collaborative business standards

A keynote session by Ole Moelskov Bech, President and Representative Director, Novo Nordisk Pharma: Create new innovation ecosystems that accelerate new medicine discovery and better digital health solutions

  • Turn ideas into medicines: embrace collaboration to new heights of innovative value creation for patients
  • Re-imagine the best way to make innovative medicine accessible to patients throughout the world.

Ole Moelskov Bech President and Representative Director Novo Nordisk Pharma AG

10:15 - Drive healthcare sustainability

Beyond the Pill: Strategic collaboration with external partners to create new medical solutions and contribute to patients

  • Promote collaboration and coordination with key stakeholders across industries.
  • Maximize the quality of personalized treatment and treatment outcomes by analyzing and visualizing the patient journey.
  • Contribute to the realization of value-based healthcare by focusing on medical issues surrounding cancer patients.

Takafumi Horii Senior Vice President, Head of Japan Oncology Business Unit, Global Oncology Business Unit Takeda Pharmaceutical Co., Ltd.

10:15 - Drive healthcare sustainability

Patient-Centric & integrated digital transformation with Salesforce Health Cloud

  • Realize patient-centered DX where patients and various health care providers share the vision and challenges, and where each patient can receive optimal health care in a convenient, prompt and continuous manner through integrated DX rather than partial optimization.
  • Leverage Salesforce Health Cloud to integrate data from EHRs, PHRs, various mobile apps, and healthcare devices to create a "patient 360 view" of the patient and all of their care on one platform.
  • Utilize the Salesforce Platform to enable seamless collaboration among various healthcare providers, including pharmaceutical companies, medical institutions, pharmacies, and local governments, with a focus on patients.
  • Realize an environment in which each patient can receive optimal healthcare quickly and continuously, through the active involvement of patients themselves in their own healthcare using digital technology.

Kazuaki Hayata Senior Manager, Healthcare & Life Sciences Industry, Industries Transformation salesforce.com, Inc.

11:15 - Drive healthcare sustainability

The road to value-based medicine: Explore the latest regulations, technologies and platforms enabling communication of the value of the medicine
Panel session by Government speaker, academia and pharma experts

  • Drive healthcare sustainability: understand the changing role of industry in Japan’s health infrastructure enabled by new digital transformation
  • How new understanding of medical value will drive a sustainable future and create new business opportunities for pharma

Yasuo Iimura Director for Policy Planning, Healthcare Industries Division, Commerce and Service Industry Policy Group Ministry of Economy, Trade and Industry

Tomohiro Kuroda CIO / Professor, Hospital Kyoto University

Masatoshi Morita Head of Japan, Bone Health Mission UCB Japan

Maya Mamiya Senior Manager, Government Affairs, Corporate Affairs Eli Lilly Japan K.K.

12:15pm - Patient-centric value is business value

The "experience" of people with diseases (patients) will change pharmaceuticals and medicine! Evolve into a new pharmaceutical business that improve outcomes cooperatively with patients

  • Confronting the current status-quo in Japan: let’s make the patient voice essential and valued across the value chain, including HTA and pricing decision-making
  • A blueprint for action with lessons learnt from the difference in activities between the U.S. and Japan
  • The quest for a new way of doing pharma that doesn't need the term "patient centricity" to face the challenge of improving outcomes with patients

Takeshi Shukunobe CEO PPEC (General Incorporated Association)

Hiroyuki Higashiyama Director, Patient Centricity Astellas Pharma Inc.

1:00pm - Data driven customer engagement means valued customer engagement

Maximize market impact by generating actionable insights from “Deep Data”

  • Generate actionable insights from Deep Data by reviewing data generation processes and development strategies to maximize market impact
  • Promote the communication of value in omnichannel marketing and digital marketing

Donatas Grabliauskas Marketing & Strategic Liaison Director, Oncology business unit Johnson & Johnson

1:00pm - Data driven customer engagement means valued customer engagement

The Current State of Pharma Customer Centricity in Japan: Lessons that can Drive your Company’s Performance Beyond Customer Centric

  • How important is customer centricity in driving competitiveness in the Pharma industry in Japan? Which is more important, physician centricity or patient centricity?
  • Which companies are perceived best in customer centricity within oncology / hematology / immunology in Japan? Japanese or US / Europe headquartered companies?
  • Which characteristics of HCP interactions can drive physician centricity? Is quality or quantity of the interactions more important? How important is personalization of the HCP interactions?
  • What is the importance of digital interactions in driving physician centricity? What is the evolution of omnichannel / digital communication in pre-during-post Covid-19 era? Which digital channels will remain important? Push or Pull? Commercial or Medical? How important is the strength of “the MR and HCP relationship” and can it accelerate digital adoption?

Joeri De Haes Director Japan & Asia Pacific, Market Strategies Trilations

1:45pm - Data driven customer engagement means valued customer engagement

Case study:
Centre communication on customer preference – a new collaboration model between Commercial Excellence and IT

  • How to identify roles and priorities to respond quickly to desired changes and new customer engagement
  • Build internal and external partnerships to communicate value in new ways
  • Collaborative session with nominated members from AstraZeneca's Commercial Excellence and Digital Transformation teams

Atsushi Yamashita Director, Customer Engagement Transformation, Commercial Excellence AstraZeneca K.K.

Misaki Ohkawara Group Manager/Business relationship Manager, Digital Transformation Group, Information & Digital Solutions AstraZeneca K.K.

1:45pm - Data driven customer engagement means valued customer engagement

How APAC teams are adding value to stakeholder engagement

  • Achieve more with fewer meetings - how Japanese and APAC teams are adopting a hybrid engagement model to gain deeper, more actionable insights from stakeholders
  • How to gain more diverse perspectives from collaborators with an engagement strategy that maximises interaction and removes regional and language constraints
  • Focus on patient centricity with a platform that privately and securely gives patients a voice, resulting in a valuable insights stream that can be used to improve patient quality of life.

Ken Hersche Senior Director, Client Success Within3

1:45pm - Data driven customer engagement means valued customer engagement

Promote the appropriate use of drugs through digital Marketing that connects hearts and minds

  • How to analyze HCP behavioral data to provide information at the "right time"
  • How to create scenarios that enable future-oriented "proactive" engagement?
  • AI analysis of behavioral data to provide the information needed today in tomorrow's communication

Kyoichi Nishimoto Head, Customer Engagement Innovation Amgen K.K.

Day 2 – September 15: Keynotes & RWE & Medical

9:00am - Medical innovation in the age of information: Toward value-based medicine

The Pursuit of the Beauty of Science (Efficacy) and the Quest for Freedom
Are you ready to take on the "loneliness" and "responsibility" of patient-centricity?

  • What is the difference between the concept of patient-centricity and the similar but different nature of the "patient-centricity" structure in effectiveness?
  • Awareness of blind spots: Reconsider how to expand perspectives and discussions in the age of information-based medicine, based on efforts to extract important information (highly relevant and important information) that users are not aware of in community-based content
  • What is the best we can do in the struggle between the pursuit of efficacy and the improvement of scientific literacy?

Daisuke Tanaka Director, Venture Support Office
Economic Affairs Division
Health Policy Bureau
Ministry of Health, Labour and Welfare (MHLW), Japan

Eiji Aramaki Professor, Social Computing Laboratory Nara Institute of Science and Technology (NAIST)

Kotonari Aoki Department Manager, Real World Data Science Dept. Chugai Pharmaceutical Co.,Ltd.

Osamu Komiyama Senior Manager, Statistical Research & Data Science Group Pfizer R&D Japan

10:30am - Keynote: Cement new diverse and collaborative business standards

Embrace new diversity standards to provide new value across your business and surpass external stakeholder expectations

  • Less talk, more action: rethink the leadership required in a diverse environment and set new frameworks to achieve ambitious targets
  • Gain broader, more representative insights to overcome internal biases and find new opportunities for innovation, improving current business processes
  • How internal diversity can aid patient engagement and further drive patient-centric transformation

Susie Barnes Member of the Board, Country Medical Director
VP and Head of Japan Medical and Development
GlaxoSmithKline K.K.

Hideko Ikeda Managing Director Merck Vietnam Company

10:30am - Keynote: Cement new diverse and collaborative business standards

Sustainability in Pharma:Access and Financial Returns

  • How is the role of access evolving in pharma, from a term in the revenue equation to an independent metric?
  • Why does it matter? How do companies think about this?
  • How can pharma frame the trade-offs between longer term sustainability and current support for patients?
  • What are some examples from industry?
  • How can pharma broaden its lens to include the full range of stakeholders and ensure the trade-off includes them?
  • Why are we using the word “ecosystem” so much recently?
  • How does this new frame influence the planning and platform development processes for pharma launch and support?

Rob Arnold Executive Vice President EVERSANA

11:45am - Medical innovation in the age of information: Toward value-based medicine

KOL presentation:
Medicine in the Information Age

  • Redefine medical care as a social activity: A world in which hospital functions are embedded in society and medical services are a part of daily life
  • Create an information infrastructure in actual clinical settings, analyze active clinical information, and realize practical information support using acquired knowledge
  • Work together to create a new form of medical care and medicine in the information age based on the knowledge gained from the generation, transmission, conversion, accumulation, and use of medical information

Tomohiro Kuroda CIO / Professor, Hospital Kyoto University

11:45am - Medical innovation in the age of information: Toward value-based medicine

Make the most of the lessons learned from challenges in utilizing real-world data during infectious disease outbreaks

  • Sort out the technical challenges of evidence generation through the epidemic of a new coronavirus infection and the innovations that quietly occurred.
  • Learn about the initial quantitative assessment of the impact on socioeconomic activities and the associated demand for medical and pharmaceutical services
  • Understand the necessity of efforts to capture new research demand based on future epidemic dynamics in a collaborative structure such as COCN

Hiroshi Nishiura Professor, Graduate School of Medicine Kyoto University

12:30pm - Empower Medical Affairs to deliver new stakeholder value

The ideal state for Medical Affairs to achieve better results than ever before

  • Examine the need for face-to-face communication in medical affairs based on statistics
  • Learn from findings from virtual engagement in the search for medical affairs under COVID-19
  • What should be the ideal state of medical affairs to achieve better results than ever before, based on the results demonstrated here?

Kenichiro Shimizu Japan Medical Affairs Director, Abbott Diabetes Care, Japan Medical Affairs Abbott Japan LLC

12:30pm - Empower Medical Affairs to deliver new stakeholder value

Figure out the new role of medical affairs in the transforming framework to provide new value both internally and externally

  • Define performance indicators that reflect the changing healthcare environment, by reviewing the results of five years of medical affairs standardization
  • Clarify the role of MSLs inside and outside the organization, and meet the evolving needs of healthcare professionals and patients with a new digital framework

Hideyuki Shiba Director, Medical Excellence AstraZeneca K.K.

1:15pm - Integrated-evidence generation: Unlock value-based care

How Medical Affairs is driving new connectivity amongst healthcare stakeholders enabling value-based decision-making

  • How collaboration between local governments, academia, and AstraZeneca led to the creation of a healthy society through the improvement of community health care by supporting medical insurance policy (Kyoto-city DB)
  • Contribute to the resolution of social issues such as healthcare disparities through the medical affairs-led educational programs and the generation of evidence (YHP)
  • Support the establishment of a health care system in which citizens and patients themselves take responsibility for their own health management through PHRs by establishing evidence as well as science (PHR)

Masahisa Jinushi Head of Oncology Medical, Medical Division AstraZeneca K.K.

1:15pm - Integrated-evidence generation: Unlock value-based care

Generate evidence enabling precision medicine with true utilization of medical data platforms

  • How platform technology can structure medical data, including biometric data, to enable faster delivery of care to patients and contribute to preventive medicine
  • Unlock the value of current data silos between society and medical practice
  • The key to building a platform to provide a solid foundation of basic and clinical research

Manabu Muto Professor / Head, Department of Therapeutic Oncology, Graduate School of Medicine / Department of Clinical Oncology Kyoto University Hospital (Japan)

1:15pm - Integrated-evidence generation: Unlock value-based care

Accelerate R&D of rare cancers and genomic medicine with new data collection techniques
- Insights from Industry-academia collaboration and MHLW's special research team initiatives

  • Use real-world data to reduce the time and increase the efficiency of clinical trials for rare diseases
  • How to accumulate large data pools for patients with rare cancers and inform treatment selection to the characteristics of the disease, including molecular biological evaluation indicators (biomarkers)
  • Deliver new drugs to patients with rare cancers more quickly and in greater numbers by deepening the understanding of proportionality and clarifying the optimal balance of quality and reliability according to the purpose of clinical trials

Kenichi Nakamura Director, Department of International Clinical Development National Cancer Center Hospital

3:00pm - Coffee chat table

Hello, healthy world - The future world and access to healthcare

To develop a world where people are guided to appropriate care and to maximize medical outcomes, we would like to have an interactive discussion with you on the following topics.

  • Ubie's mission: "To develop a healthcare guide for everyone": Using the power of technology to minimize the "medical information gap" between patients and doctors and create a world where everyone can be guided to the proper healthcare at the right time.
  • Introduction of Ubie's pharmaceutical solutions: What Ubie's pharmaceutical solutions can do for you now and what we are going to do soon
  • Case study: Introduction of Ubie's work with leading pharmaceutical companies

Yoshinori Abe MD, Co-Founder & CEO Ubie, Inc.

Akira Oka Business Development Ubie, Inc.

Day 3 – September 16: Keynotes & Digital Clinical Innovation

9:00am - Next dimension in virtual external-facing innovation

Next dimension in virtual external-facing innovation - presentation by Jovelle’s avatar

  • Experience the true power of digital to achieve excellent customer engagement
  • See how the digital twin platform can empower Crohn’s Disease patients in a unique way
  • Embody collaborative approach to manage Parkinson’s Disease - the case study of Care for One project with the government and other non-pharma groups

Jovelle L. Fernandez, MD, PhD, FPOGS Head
Japan Medical Office
Japan Pharma Business Unit
Takeda Pharmaceutical Co., Ltd.

9:00am - Next dimension in virtual external-facing innovation

A Keynote session:Driving Engagement for Healthcare Professionals in Japan

  • In July 2021 Wiley conducted research amongst healthcare practitioners to learn more about changing information behaviours.
  • Wiley surveyed over 1,000 healthcare professionals (HCPs) globally, about their content consumption, preferences, and habits to understand how information on the page/screen translates to clinical practice.

Peter de Jong Global Director, Health, Corporate Sales Wiley

9:45am - R&D has lift off!

A more holistic approach to commercializing medical innovations

  • From the perspective of a physician and clinical leader: Create more patient-centric medicine by forming a culture that visualizes the patient behind the data
  • How to evaluate the outcomes from a more varied perspective, including angles such as Quality of Life (QoL), to better demonstrate the value of medicine to patients
  • Toward a world where the medicine you want to use is available

Naotsugu Oyama Corporate Officer Head, Clinical Development&Analytics Japan, Global Drug Development Division Novartis Pharma K.K.

9:45am - R&D has lift off!

From operations to strategy:
Leverage Japan's strength in drug development to increase value to the global pharmaceutical industry

  • Visualize the changing nature of pharma’s value to healthcare and aim for attractive companies, industries, and markets in which to invest at the global standard
  • How to uncover early assets and deliver them to patients as drugs and medical treatments
  • Not just operations: Increase value by building strategic mechanisms and novel collaborations

Makoto Sugita Executive Officer, Vice President, R&D Japan Bristol Myers Squibb

9:45am - R&D has lift off!

The shift towards digitization in clinical trials - Parameters to accelerate and optimize technology strategy

  • Successfully leverage digital technology for clinical trials requires a proven digital strategy. Define the four pillars of the digital model for clinical research that moves large sponsors forward - digital leadership, a data-driven approach, patient centricity, and a culture of innovation.
  • Trial success relies on driving the pace, flexibility, and adoption of new capabilities such as flexible integration platforms that can help 100% remote trials, hybrid trials, as well as traditional site visit trials.
  • Technology advances have improved operational efficiency, patient experiences, and data analysis for clinical trials. The future will bring more technology into clinical processes as virtual trials proliferate.

Motohide Nishi VP, Japan Professional Services Medidata

10:45am - Achieve patient-preferred clinical trials

Case study from a data science perspective: Generate value from diverse data in the pharmaceutical lifecycle from clinical development to post-marketing

  • Learn about the importance of design in the current situation where data solutions themselves are diversifying along with the diversification of data
  • Maximize product value by combining new data solutions and RWD utilization based on patient needs
  • Transform the data delivery that enables new clinical trials using data including remote data that is closely related to the patient's journey

Keiko Yokoyama Senior Manager, Japan Data Sciences, Scientific Data Solutions and Communications, MDU-Japan Eli Lilly Japan K.K.

10:45am - Achieve patient-preferred clinical trials

Utilise digital tools for clinical trials for sustainable data construction

  • Doing the best with current data: Learn about digital solutions and datamix approaches for clinical development
  • Awareness of the innovation dilemma: How do we confront market-changing innovations?
  • The best way to build data when we understand the essence of enabling patients to access the right drug at the right time

Takashi Moriya Director, Evidence Generation, Medical Affairs Janssen Pharmaceutical K.K.

Masayuki Katsumata Head, Value Evidence & Outcomes, Japan Medical and Development GlaxoSmithKline Japan

10:45am - Achieve patient-preferred clinical trials

Patient centricity in post-corona: Generate evidence from clinical trials and the real world

  • New clinical trials for the post-coronary era
  • Study design based on patient-centricity and the generation of real-world evidence
  • Consideration of the value of observational studies in effective registry data collection and evidence generation in view of future database development

Yuji Fujii Senior Client Relationship Director, Enterprise Accounts Japan Parexel International

Satoshi Yoshizumi Sr. Clinical Operations Leader Parexel International

12:20pm - Foster a new science ecosystem to ensure an innovative future

Creating a more collaborative scientific infrastructure in Japan to foster novel scientific innovation

  • The vision for the “science ecosystem” connecting people to people, breaking down industry silos, and increasing the number of human resources across fields.
  • Build stakeholder communication frameworks by leveraging the power of community
  • Promote Japan's contribution to the global pharmaceutical industry by fostering innovations in Japan

Taruho Kuroda Senior Director, LEO Science & Tech Hub LEO Pharma

12:20pm - Foster a new science ecosystem to ensure an innovative future

A deep dive into the Street Medical City Initiative leveraging design-thinking and gamification to drive science

  • Achieve multifaceted development: What is the best way for varied stakeholder groups to collaborate?
  • A model case of “Street Medicine” by Astellas Pharma Inc. and Tokyo University of the Arts: How to realize medical care in everyday life through gamification
  • The key to formulating and implementing infinite ideas through design thinking

Takanori Takebe Professor, Founding director, Institute of Research, Communication Design Center; Advanced Medical Research Center Tokyo Medical and Dental University, Yokohama City University

12:20pm - Foster a new science ecosystem to ensure an innovative future

AI drug discovery and predictive medicine: A new combination of wizard-level experts

  • Improve the accuracy of predictive medicine by using AI-based digital biomarkers to create new medical value
  • Enable a "broad and deep" perspective in drug development with analysis of compounds and cellular structures based on network analysis
  • New business in the age of life watching care: How to share the "Magic Inheritance" level best practices of gurus through the newest technology
  • Create new evidence-based medicine that meets the needs of patients, healthcare providers, pharmaceuticals, and all stakeholders involved by analyzing best practices in medication and medical interventions

Ko Ishiyama President & CEO ExaWizards Inc.

1:20pm - Achieve patient-preferred clinical trials

Behind the Scenes at the KISEKI Clinical Trials:
Innovation is born when a patient's wish is scientifically supported

  • How patients' thoughts" in patient-initiated and physician-led clinical trials become power to overcome "despair
  • How to build consensus within a pharmaceutical company: Behind the scenes to see how patients' thoughts were used to drive consensus at a strategic level
  • Learn about the tips for joint clinical trials with patients:In order to encourage people to follow the momentum created by the KISEKI clinical trial

Kazuo Hasegawa Founder Lung Cancer Patients Network ONE STEP

Kazuhiko Nakagawa Professor, Department of Medical Oncology Kindai University Faculty of Medicine

Masahisa Jinushi Head of Oncology Medical, Medical Division AstraZeneca K.K.

On Demand: Panels

Achieve patient-preferred clinical trials

What is the true state of medical data? - Let's think about it by backcasting from the "Connected City" in future 

  • Clarify the ideal state of medical data from a broad perspective that transcends industry boundaries
  • Build a framework for the future of medical data.
  • Learn how to collaborate across existing disciplines by truly understanding the best way to utilize data

Kanae Togo Senior Manager, Outcome & Evidence, Health & Value Pfizer Japan Inc.

Norihiro Kobayashi Director, Digital Intelligence Dept. SHIONOGI & CO., LTD.

Masayuki Katsumata Head, Value Evidence & Outcomes, Japan Medical and Development GlaxoSmithKline Japan

Takashi Moriya Director, Evidence Generation, Medical Affairs Janssen Pharmaceutical K.K.

Miyuki Baillie Vice President, Science Group, Japan Clarivate

Integrated-evidence generation: Unlock value-based care

Generating evidence in a time of great transformation: Open medical data and new combinations for a healthier society

  • More information coming soon…

Yasuyuki Katayama Associate Vice President/ Head of Medical Affairs/ Executive Officer MSD Japan

Hiroyuki Taruno Japanese Foundation For Cancer Research
Cancer Institute Hospital

Takashi Moriya Director, Evidence Generation, Medical Affairs Janssen Pharmaceutical K.K.

Satoshi Yoshizumi Sr. Clinical Operations Leader Parexel International

Yuji Fujii Senior Client Relationship Director, Enterprise Accounts Japan Parexel International

Digital transformation =Human transformation

How we can confront the new age of "digital & human" transformation

  • Gain a bird's eye view of the future of digital transformation and learn the perspective, thinking, and behavioral changes necessary for transformation.
  • Rethink team management that encompasses both the management perspective and consideration for the frontline, and is appropriate for the future.
  • Rethink team management that encompasses both the management perspective and compassion for the field
  • Review the challenges of promoting speedy work processes and agile development that are optimal for digital transformation

Masaru Otsuka Strategic Digital Japan Head, Enterprise Digital Takeda Pharmaceutical Co., Ltd.

Junko Kimura Sr. Director, Commercial Operations Gilead Sciences K.K.

Shinya Suda Senior Vice President, Information Systems Astellas Pharma Inc.

A new way of sales information provision

A new way of sales information provision - How to apply the needs in COVID19 environment to the future channelomics design

  • Understand the changing trends in "information provision" and identify the desired elements of new communication in the future
  • Design and implement an environment in which HCPs can obtain the information they want, in a preferable way 
  • Create an internal team and to provide value to HCPs by creating an environment where we ourselves can feel comfortable

Takafumi Horii Senior Vice President, Head of Japan Oncology Business Unit, Global Oncology Business Unit Takeda Pharmaceutical Co., Ltd.

Seigo Noda Marketing Senior Director, Renal, CVRM/GI Business Unit AstraZeneca KK

Tomoo Miyake Director, Sales Planning, Liver Business Unit, Japan Gilead Sciences K.K.

Interactive: Workshops & Roundtables

Achieve patient-preferred clinical trials

Roundtable A new model of patient centricity in a data-driven society

  • More information coming soon…

Empower Medical Affairs to deliver new stakeholder value

Roundtable Learn from a case study of real-world data integration and combination

  • More information coming soon…

Data driven customer engagement means valued customer engagement

Workshop What is the organizational structure and utilization method for cross-company RWD utilization?

  • More information coming soon…

Data driven customer engagement means valued customer engagement

Workshop Why data-driven market visualization is essential for the future of business

  • More information coming soon…

Data driven customer engagement means valued customer engagement

Roundtable Find the optimal balance between digital and analogue to satisfy human sensitivity

  • More information coming soon…

Data driven customer engagement means valued customer engagement

Roundtable Marketing models based on three-dimensional storytelling and effective use of data

  • More information coming soon…

Day 1 – September 14: Keynotes & Commercial Excellence

9:00am - Opening C-Suite Interviews

Reuters Editorial 1-on-1 interview with Christophe, CEO, Takeda

  • Pioneer mobilization of global leaders to shape the principles, policies and partnerships needed in this challenging new context

More information will be revealed soon.

Christophe Weber President, Chief Executive Officer (CEO) and Representative Director Takeda Pharmaceutical Co., Ltd.

9:30 - Cement new diverse and collaborative business standards

Hello, Healthy World

  • When I worked as a physician, I encountered a fundamental question: "Why do people lose their lives because they cannot meet the proper treatment or drug?"
  • AI "Monshin"(interview), the "gateway to medical care," rapidly penetrates the medical institutions and patients.
  • Ubie empowers doctors and guides people to the right medical care. And we are ready to deliver the medicine to every patient who needs them.
  • How do pharmaceutical companies and Ubie collaborate to guide people to the right care and medicine? I will tell the story based on the actual case studies.

Yoshinori Abe MD, Co-Founder & CEO Ubie, Inc.

9:30 - Cement new diverse and collaborative business standards

A keynote session by Ole Moelskov Bech, President and Representative Director, Novo Nordisk Pharma: Create new innovation ecosystems that accelerate new medicine discovery and better digital health solutions

  • Turn ideas into medicines: embrace collaboration to new heights of innovative value creation for patients
  • Re-imagine the best way to make innovative medicine accessible to patients throughout the world.

Ole Moelskov Bech President and Representative Director Novo Nordisk Pharma AG

10:15 - Drive healthcare sustainability

Beyond the Pill: Strategic collaboration with external partners to create new medical solutions and contribute to patients

  • Promote collaboration and coordination with key stakeholders across industries.
  • Maximize the quality of personalized treatment and treatment outcomes by analyzing and visualizing the patient journey.
  • Contribute to the realization of value-based healthcare by focusing on medical issues surrounding cancer patients.

Takafumi Horii Senior Vice President, Head of Japan Oncology Business Unit, Global Oncology Business Unit Takeda Pharmaceutical Co., Ltd.

10:15 - Drive healthcare sustainability

Patient-Centric & integrated digital transformation with Salesforce Health Cloud

  • Realize patient-centered DX where patients and various health care providers share the vision and challenges, and where each patient can receive optimal health care in a convenient, prompt and continuous manner through integrated DX rather than partial optimization.
  • Leverage Salesforce Health Cloud to integrate data from EHRs, PHRs, various mobile apps, and healthcare devices to create a "patient 360 view" of the patient and all of their care on one platform.
  • Utilize the Salesforce Platform to enable seamless collaboration among various healthcare providers, including pharmaceutical companies, medical institutions, pharmacies, and local governments, with a focus on patients.
  • Realize an environment in which each patient can receive optimal healthcare quickly and continuously, through the active involvement of patients themselves in their own healthcare using digital technology.

Kazuaki Hayata Senior Manager, Healthcare & Life Sciences Industry, Industries Transformation salesforce.com, Inc.

11:15 - Drive healthcare sustainability

The road to value-based medicine: Explore the latest regulations, technologies and platforms enabling communication of the value of the medicine
Panel session by Government speaker, academia and pharma experts

  • Drive healthcare sustainability: understand the changing role of industry in Japan’s health infrastructure enabled by new digital transformation
  • How new understanding of medical value will drive a sustainable future and create new business opportunities for pharma

Yasuo Iimura Director for Policy Planning, Healthcare Industries Division, Commerce and Service Industry Policy Group Ministry of Economy, Trade and Industry

Tomohiro Kuroda CIO / Professor, Hospital Kyoto University

Masatoshi Morita Head of Japan, Bone Health Mission UCB Japan

Maya Mamiya Senior Manager, Government Affairs, Corporate Affairs Eli Lilly Japan K.K.

12:15pm - Patient-centric value is business value

The "experience" of people with diseases (patients) will change pharmaceuticals and medicine! Evolve into a new pharmaceutical business that improve outcomes cooperatively with patients

  • Confronting the current status-quo in Japan: let’s make the patient voice essential and valued across the value chain, including HTA and pricing decision-making
  • A blueprint for action with lessons learnt from the difference in activities between the U.S. and Japan
  • The quest for a new way of doing pharma that doesn't need the term "patient centricity" to face the challenge of improving outcomes with patients

Takeshi Shukunobe CEO PPEC (General Incorporated Association)

Hiroyuki Higashiyama Director, Patient Centricity Astellas Pharma Inc.

1:00pm - Data driven customer engagement means valued customer engagement

Maximize market impact by generating actionable insights from “Deep Data”

  • Generate actionable insights from Deep Data by reviewing data generation processes and development strategies to maximize market impact
  • Promote the communication of value in omnichannel marketing and digital marketing

Donatas Grabliauskas Marketing & Strategic Liaison Director, Oncology business unit Johnson & Johnson

1:00pm - Data driven customer engagement means valued customer engagement

The Current State of Pharma Customer Centricity in Japan: Lessons that can Drive your Company’s Performance Beyond Customer Centric

  • How important is customer centricity in driving competitiveness in the Pharma industry in Japan? Which is more important, physician centricity or patient centricity?
  • Which companies are perceived best in customer centricity within oncology / hematology / immunology in Japan? Japanese or US / Europe headquartered companies?
  • Which characteristics of HCP interactions can drive physician centricity? Is quality or quantity of the interactions more important? How important is personalization of the HCP interactions?
  • What is the importance of digital interactions in driving physician centricity? What is the evolution of omnichannel / digital communication in pre-during-post Covid-19 era? Which digital channels will remain important? Push or Pull? Commercial or Medical? How important is the strength of “the MR and HCP relationship” and can it accelerate digital adoption?

Joeri De Haes Director Japan & Asia Pacific, Market Strategies Trilations

1:45pm - Data driven customer engagement means valued customer engagement

Case study:
Centre communication on customer preference – a new collaboration model between Commercial Excellence and IT

  • How to identify roles and priorities to respond quickly to desired changes and new customer engagement
  • Build internal and external partnerships to communicate value in new ways
  • Collaborative session with nominated members from AstraZeneca's Commercial Excellence and Digital Transformation teams

Atsushi Yamashita Director, Customer Engagement Transformation, Commercial Excellence AstraZeneca K.K.

Misaki Ohkawara Group Manager/Business relationship Manager, Digital Transformation Group, Information & Digital Solutions AstraZeneca K.K.

1:45pm - Data driven customer engagement means valued customer engagement

How APAC teams are adding value to stakeholder engagement

  • Achieve more with fewer meetings - how Japanese and APAC teams are adopting a hybrid engagement model to gain deeper, more actionable insights from stakeholders
  • How to gain more diverse perspectives from collaborators with an engagement strategy that maximises interaction and removes regional and language constraints
  • Focus on patient centricity with a platform that privately and securely gives patients a voice, resulting in a valuable insights stream that can be used to improve patient quality of life.

Ken Hersche Senior Director, Client Success Within3

1:45pm - Data driven customer engagement means valued customer engagement

Promote the appropriate use of drugs through digital Marketing that connects hearts and minds

  • How to analyze HCP behavioral data to provide information at the "right time"
  • How to create scenarios that enable future-oriented "proactive" engagement?
  • AI analysis of behavioral data to provide the information needed today in tomorrow's communication

Kyoichi Nishimoto Head, Customer Engagement Innovation Amgen K.K.

Day 2 – September 15: Keynotes & RWE & Medical

9:00am - Medical innovation in the age of information: Toward value-based medicine

The Pursuit of the Beauty of Science (Efficacy) and the Quest for Freedom
Are you ready to take on the "loneliness" and "responsibility" of patient-centricity?

  • What is the difference between the concept of patient-centricity and the similar but different nature of the "patient-centricity" structure in effectiveness?
  • Awareness of blind spots: Reconsider how to expand perspectives and discussions in the age of information-based medicine, based on efforts to extract important information (highly relevant and important information) that users are not aware of in community-based content
  • What is the best we can do in the struggle between the pursuit of efficacy and the improvement of scientific literacy?

Daisuke Tanaka Director, Venture Support Office
Economic Affairs Division
Health Policy Bureau
Ministry of Health, Labour and Welfare (MHLW), Japan

Eiji Aramaki Professor, Social Computing Laboratory Nara Institute of Science and Technology (NAIST)

Kotonari Aoki Department Manager, Real World Data Science Dept. Chugai Pharmaceutical Co.,Ltd.

Osamu Komiyama Senior Manager, Statistical Research & Data Science Group Pfizer R&D Japan

10:30am - Keynote: Cement new diverse and collaborative business standards

Embrace new diversity standards to provide new value across your business and surpass external stakeholder expectations

  • Less talk, more action: rethink the leadership required in a diverse environment and set new frameworks to achieve ambitious targets
  • Gain broader, more representative insights to overcome internal biases and find new opportunities for innovation, improving current business processes
  • How internal diversity can aid patient engagement and further drive patient-centric transformation

Susie Barnes Member of the Board, Country Medical Director
VP and Head of Japan Medical and Development
GlaxoSmithKline K.K.

Hideko Ikeda Managing Director Merck Vietnam Company

10:30am - Keynote: Cement new diverse and collaborative business standards

Sustainability in Pharma:Access and Financial Returns

  • How is the role of access evolving in pharma, from a term in the revenue equation to an independent metric?
  • Why does it matter? How do companies think about this?
  • How can pharma frame the trade-offs between longer term sustainability and current support for patients?
  • What are some examples from industry?
  • How can pharma broaden its lens to include the full range of stakeholders and ensure the trade-off includes them?
  • Why are we using the word “ecosystem” so much recently?
  • How does this new frame influence the planning and platform development processes for pharma launch and support?

Rob Arnold Executive Vice President EVERSANA

11:45am - Medical innovation in the age of information: Toward value-based medicine

KOL presentation:
Medicine in the Information Age

  • Redefine medical care as a social activity: A world in which hospital functions are embedded in society and medical services are a part of daily life
  • Create an information infrastructure in actual clinical settings, analyze active clinical information, and realize practical information support using acquired knowledge
  • Work together to create a new form of medical care and medicine in the information age based on the knowledge gained from the generation, transmission, conversion, accumulation, and use of medical information

Tomohiro Kuroda CIO / Professor, Hospital Kyoto University

11:45am - Medical innovation in the age of information: Toward value-based medicine

Make the most of the lessons learned from challenges in utilizing real-world data during infectious disease outbreaks

  • Sort out the technical challenges of evidence generation through the epidemic of a new coronavirus infection and the innovations that quietly occurred.
  • Learn about the initial quantitative assessment of the impact on socioeconomic activities and the associated demand for medical and pharmaceutical services
  • Understand the necessity of efforts to capture new research demand based on future epidemic dynamics in a collaborative structure such as COCN

Hiroshi Nishiura Professor, Graduate School of Medicine Kyoto University

12:30pm - Empower Medical Affairs to deliver new stakeholder value

The ideal state for Medical Affairs to achieve better results than ever before

  • Examine the need for face-to-face communication in medical affairs based on statistics
  • Learn from findings from virtual engagement in the search for medical affairs under COVID-19
  • What should be the ideal state of medical affairs to achieve better results than ever before, based on the results demonstrated here?

Kenichiro Shimizu Japan Medical Affairs Director, Abbott Diabetes Care, Japan Medical Affairs Abbott Japan LLC

12:30pm - Empower Medical Affairs to deliver new stakeholder value

Figure out the new role of medical affairs in the transforming framework to provide new value both internally and externally

  • Define performance indicators that reflect the changing healthcare environment, by reviewing the results of five years of medical affairs standardization
  • Clarify the role of MSLs inside and outside the organization, and meet the evolving needs of healthcare professionals and patients with a new digital framework

Hideyuki Shiba Director, Medical Excellence AstraZeneca K.K.

1:15pm - Integrated-evidence generation: Unlock value-based care

How Medical Affairs is driving new connectivity amongst healthcare stakeholders enabling value-based decision-making

  • How collaboration between local governments, academia, and AstraZeneca led to the creation of a healthy society through the improvement of community health care by supporting medical insurance policy (Kyoto-city DB)
  • Contribute to the resolution of social issues such as healthcare disparities through the medical affairs-led educational programs and the generation of evidence (YHP)
  • Support the establishment of a health care system in which citizens and patients themselves take responsibility for their own health management through PHRs by establishing evidence as well as science (PHR)

Masahisa Jinushi Head of Oncology Medical, Medical Division AstraZeneca K.K.

1:15pm - Integrated-evidence generation: Unlock value-based care

Generate evidence enabling precision medicine with true utilization of medical data platforms

  • How platform technology can structure medical data, including biometric data, to enable faster delivery of care to patients and contribute to preventive medicine
  • Unlock the value of current data silos between society and medical practice
  • The key to building a platform to provide a solid foundation of basic and clinical research

Manabu Muto Professor / Head, Department of Therapeutic Oncology, Graduate School of Medicine / Department of Clinical Oncology Kyoto University Hospital (Japan)

1:15pm - Integrated-evidence generation: Unlock value-based care

Accelerate R&D of rare cancers and genomic medicine with new data collection techniques
- Insights from Industry-academia collaboration and MHLW's special research team initiatives

  • Use real-world data to reduce the time and increase the efficiency of clinical trials for rare diseases
  • How to accumulate large data pools for patients with rare cancers and inform treatment selection to the characteristics of the disease, including molecular biological evaluation indicators (biomarkers)
  • Deliver new drugs to patients with rare cancers more quickly and in greater numbers by deepening the understanding of proportionality and clarifying the optimal balance of quality and reliability according to the purpose of clinical trials

Kenichi Nakamura Director, Department of International Clinical Development National Cancer Center Hospital

3:00pm - Coffee chat table

Hello, healthy world - The future world and access to healthcare

To develop a world where people are guided to appropriate care and to maximize medical outcomes, we would like to have an interactive discussion with you on the following topics.

  • Ubie's mission: "To develop a healthcare guide for everyone": Using the power of technology to minimize the "medical information gap" between patients and doctors and create a world where everyone can be guided to the proper healthcare at the right time.
  • Introduction of Ubie's pharmaceutical solutions: What Ubie's pharmaceutical solutions can do for you now and what we are going to do soon
  • Case study: Introduction of Ubie's work with leading pharmaceutical companies

Yoshinori Abe MD, Co-Founder & CEO Ubie, Inc.

Akira Oka Business Development Ubie, Inc.

Day 3 – September 16: Keynotes & Digital Clinical Innovation

9:00am - Next dimension in virtual external-facing innovation

Next dimension in virtual external-facing innovation - presentation by Jovelle’s avatar

  • Experience the true power of digital to achieve excellent customer engagement
  • See how the digital twin platform can empower Crohn’s Disease patients in a unique way
  • Embody collaborative approach to manage Parkinson’s Disease - the case study of Care for One project with the government and other non-pharma groups

Jovelle L. Fernandez, MD, PhD, FPOGS Head
Japan Medical Office
Japan Pharma Business Unit
Takeda Pharmaceutical Co., Ltd.

9:00am - Next dimension in virtual external-facing innovation

A Keynote session:Driving Engagement for Healthcare Professionals in Japan

  • In July 2021 Wiley conducted research amongst healthcare practitioners to learn more about changing information behaviours.
  • Wiley surveyed over 1,000 healthcare professionals (HCPs) globally, about their content consumption, preferences, and habits to understand how information on the page/screen translates to clinical practice.

Peter de Jong Global Director, Health, Corporate Sales Wiley

9:45am - R&D has lift off!

A more holistic approach to commercializing medical innovations

  • From the perspective of a physician and clinical leader: Create more patient-centric medicine by forming a culture that visualizes the patient behind the data
  • How to evaluate the outcomes from a more varied perspective, including angles such as Quality of Life (QoL), to better demonstrate the value of medicine to patients
  • Toward a world where the medicine you want to use is available

Naotsugu Oyama Corporate Officer Head, Clinical Development&Analytics Japan, Global Drug Development Division Novartis Pharma K.K.

9:45am - R&D has lift off!

From operations to strategy:
Leverage Japan's strength in drug development to increase value to the global pharmaceutical industry

  • Visualize the changing nature of pharma’s value to healthcare and aim for attractive companies, industries, and markets in which to invest at the global standard
  • How to uncover early assets and deliver them to patients as drugs and medical treatments
  • Not just operations: Increase value by building strategic mechanisms and novel collaborations

Makoto Sugita Executive Officer, Vice President, R&D Japan Bristol Myers Squibb

9:45am - R&D has lift off!

The shift towards digitization in clinical trials - Parameters to accelerate and optimize technology strategy

  • Successfully leverage digital technology for clinical trials requires a proven digital strategy. Define the four pillars of the digital model for clinical research that moves large sponsors forward - digital leadership, a data-driven approach, patient centricity, and a culture of innovation.
  • Trial success relies on driving the pace, flexibility, and adoption of new capabilities such as flexible integration platforms that can help 100% remote trials, hybrid trials, as well as traditional site visit trials.
  • Technology advances have improved operational efficiency, patient experiences, and data analysis for clinical trials. The future will bring more technology into clinical processes as virtual trials proliferate.

Motohide Nishi VP, Japan Professional Services Medidata

10:45am - Achieve patient-preferred clinical trials

Case study from a data science perspective: Generate value from diverse data in the pharmaceutical lifecycle from clinical development to post-marketing

  • Learn about the importance of design in the current situation where data solutions themselves are diversifying along with the diversification of data
  • Maximize product value by combining new data solutions and RWD utilization based on patient needs
  • Transform the data delivery that enables new clinical trials using data including remote data that is closely related to the patient's journey

Keiko Yokoyama Senior Manager, Japan Data Sciences, Scientific Data Solutions and Communications, MDU-Japan Eli Lilly Japan K.K.

10:45am - Achieve patient-preferred clinical trials

Utilise digital tools for clinical trials for sustainable data construction

  • Doing the best with current data: Learn about digital solutions and datamix approaches for clinical development
  • Awareness of the innovation dilemma: How do we confront market-changing innovations?
  • The best way to build data when we understand the essence of enabling patients to access the right drug at the right time

Takashi Moriya Director, Evidence Generation, Medical Affairs Janssen Pharmaceutical K.K.

Masayuki Katsumata Head, Value Evidence & Outcomes, Japan Medical and Development GlaxoSmithKline Japan

10:45am - Achieve patient-preferred clinical trials

Patient centricity in post-corona: Generate evidence from clinical trials and the real world

  • New clinical trials for the post-coronary era
  • Study design based on patient-centricity and the generation of real-world evidence
  • Consideration of the value of observational studies in effective registry data collection and evidence generation in view of future database development

Yuji Fujii Senior Client Relationship Director, Enterprise Accounts Japan Parexel International

Satoshi Yoshizumi Sr. Clinical Operations Leader Parexel International

12:20pm - Foster a new science ecosystem to ensure an innovative future

Creating a more collaborative scientific infrastructure in Japan to foster novel scientific innovation

  • The vision for the “science ecosystem” connecting people to people, breaking down industry silos, and increasing the number of human resources across fields.
  • Build stakeholder communication frameworks by leveraging the power of community
  • Promote Japan's contribution to the global pharmaceutical industry by fostering innovations in Japan

Taruho Kuroda Senior Director, LEO Science & Tech Hub LEO Pharma

12:20pm - Foster a new science ecosystem to ensure an innovative future

A deep dive into the Street Medical City Initiative leveraging design-thinking and gamification to drive science

  • Achieve multifaceted development: What is the best way for varied stakeholder groups to collaborate?
  • A model case of “Street Medicine” by Astellas Pharma Inc. and Tokyo University of the Arts: How to realize medical care in everyday life through gamification
  • The key to formulating and implementing infinite ideas through design thinking

Takanori Takebe Professor, Founding director, Institute of Research, Communication Design Center; Advanced Medical Research Center Tokyo Medical and Dental University, Yokohama City University

12:20pm - Foster a new science ecosystem to ensure an innovative future

AI drug discovery and predictive medicine: A new combination of wizard-level experts

  • Improve the accuracy of predictive medicine by using AI-based digital biomarkers to create new medical value
  • Enable a "broad and deep" perspective in drug development with analysis of compounds and cellular structures based on network analysis
  • New business in the age of life watching care: How to share the "Magic Inheritance" level best practices of gurus through the newest technology
  • Create new evidence-based medicine that meets the needs of patients, healthcare providers, pharmaceuticals, and all stakeholders involved by analyzing best practices in medication and medical interventions

Ko Ishiyama President & CEO ExaWizards Inc.

1:20pm - Achieve patient-preferred clinical trials

Behind the Scenes at the KISEKI Clinical Trials:
Innovation is born when a patient's wish is scientifically supported

  • How patients' thoughts" in patient-initiated and physician-led clinical trials become power to overcome "despair
  • How to build consensus within a pharmaceutical company: Behind the scenes to see how patients' thoughts were used to drive consensus at a strategic level
  • Learn about the tips for joint clinical trials with patients:In order to encourage people to follow the momentum created by the KISEKI clinical trial

Kazuo Hasegawa Founder Lung Cancer Patients Network ONE STEP

Kazuhiko Nakagawa Professor, Department of Medical Oncology Kindai University Faculty of Medicine

Masahisa Jinushi Head of Oncology Medical, Medical Division AstraZeneca K.K.

On Demand: Panels

Achieve patient-preferred clinical trials

What is the true state of medical data? - Let's think about it by backcasting from the "Connected City" in future 

  • Clarify the ideal state of medical data from a broad perspective that transcends industry boundaries
  • Build a framework for the future of medical data.
  • Learn how to collaborate across existing disciplines by truly understanding the best way to utilize data

Kanae Togo Senior Manager, Outcome & Evidence, Health & Value Pfizer Japan Inc.

Norihiro Kobayashi Director, Digital Intelligence Dept. SHIONOGI & CO., LTD.

Masayuki Katsumata Head, Value Evidence & Outcomes, Japan Medical and Development GlaxoSmithKline Japan

Takashi Moriya Director, Evidence Generation, Medical Affairs Janssen Pharmaceutical K.K.

Miyuki Baillie Vice President, Science Group, Japan Clarivate

Integrated-evidence generation: Unlock value-based care

Generating evidence in a time of great transformation: Open medical data and new combinations for a healthier society

  • More information coming soon…

Yasuyuki Katayama Associate Vice President/ Head of Medical Affairs/ Executive Officer MSD Japan

Hiroyuki Taruno Japanese Foundation For Cancer Research
Cancer Institute Hospital

Takashi Moriya Director, Evidence Generation, Medical Affairs Janssen Pharmaceutical K.K.

Satoshi Yoshizumi Sr. Clinical Operations Leader Parexel International

Yuji Fujii Senior Client Relationship Director, Enterprise Accounts Japan Parexel International

Digital transformation =Human transformation

How we can confront the new age of "digital & human" transformation

  • Gain a bird's eye view of the future of digital transformation and learn the perspective, thinking, and behavioral changes necessary for transformation.
  • Rethink team management that encompasses both the management perspective and consideration for the frontline, and is appropriate for the future.
  • Rethink team management that encompasses both the management perspective and compassion for the field
  • Review the challenges of promoting speedy work processes and agile development that are optimal for digital transformation

Masaru Otsuka Strategic Digital Japan Head, Enterprise Digital Takeda Pharmaceutical Co., Ltd.

Junko Kimura Sr. Director, Commercial Operations Gilead Sciences K.K.

Shinya Suda Senior Vice President, Information Systems Astellas Pharma Inc.

A new way of sales information provision

A new way of sales information provision - How to apply the needs in COVID19 environment to the future channelomics design

  • Understand the changing trends in "information provision" and identify the desired elements of new communication in the future
  • Design and implement an environment in which HCPs can obtain the information they want, in a preferable way 
  • Create an internal team and to provide value to HCPs by creating an environment where we ourselves can feel comfortable

Takafumi Horii Senior Vice President, Head of Japan Oncology Business Unit, Global Oncology Business Unit Takeda Pharmaceutical Co., Ltd.

Seigo Noda Marketing Senior Director, Renal, CVRM/GI Business Unit AstraZeneca KK

Tomoo Miyake Director, Sales Planning, Liver Business Unit, Japan Gilead Sciences K.K.

Interactive: Workshops & Roundtables

Achieve patient-preferred clinical trials

Roundtable A new model of patient centricity in a data-driven society

  • More information coming soon…

Empower Medical Affairs to deliver new stakeholder value

Roundtable Learn from a case study of real-world data integration and combination

  • More information coming soon…

Data driven customer engagement means valued customer engagement

Workshop What is the organizational structure and utilization method for cross-company RWD utilization?

  • More information coming soon…

Data driven customer engagement means valued customer engagement

Workshop Why data-driven market visualization is essential for the future of business

  • More information coming soon…

Data driven customer engagement means valued customer engagement

Roundtable Find the optimal balance between digital and analogue to satisfy human sensitivity

  • More information coming soon…

Data driven customer engagement means valued customer engagement

Roundtable Marketing models based on three-dimensional storytelling and effective use of data

  • More information coming soon…